Philip W. Anderson PhD is President and Chief Executive Officer of P.W. Anderson & Partners, Ltd., based in the Washington, D.C. region.
Dr. Anderson specializes in international economic development, asset characterization research, corporate site selection and market development with an emphasis on the biotechnology, pharmaceutical and life sciences areas. Within these and other fields, he has completed principal contract research, consulting and representation projects in Germany, Russia, Sweden, Finland, Canada and the United States, to name a few.
In Estonia, Dr. Anderson served as advisor for the government, Tallinn Technical University and Tartu University on the further development of the biotechnology industry and infrastructure in that country. He also formed a European consortium to study the US-Mexican Maquiladora program as a model for the border region of EU/Finland and Russia. In the international real estate arena, Dr. Anderson has worked on numerous development and site selection efforts, including contracting with Siemens Real Estate Services of Germany to secure investors for their development projects, ranging from an entertainment sports arena to security-enhanced commercial space for IT companies.
Many European and U.S. agencies utilize the corporate recruiting strategies and lead generation systems created by Dr. Anderson. The Investment Promotion Office of the Russian Federation retained Dr. Anderson to identify western technology partners. A major accomplishment during this period was the founding of an organization of European, Asian and American scientists and government officials to facilitate the registration and delivery of western pharmaceutical products in Russia.
In addition to developing programs to help corporations, business associations and regions expand their reach internationally, Dr. Anderson has assisted a number of domestic and international universities to create intercontinental alliance opportunities in the IT and life science sectors. He also forumulated a platform from which to match basic and clinical science groups within certain universities with multi-national pharmaceutical companies for purposes of drug discovery and development research.
Dr. Anderson is a frequent guest speaker at conferences regarding commercial expansion and investment in Northern Europe, Eastern Germany and Russia and has authored more than 15 related studies. He has served on the board of several organizations, including an advisory board for Lufthansa Airlines, the Swedish-American Cultural Union and the Finnish-American Business Council in Washington, D.C. In recognition of distinguished service in furthering Swedish-American relations, Dr. Anderson was awarded the Royal Medal by King Carl XVI Gustav of Sweden.